Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
Data Mixed In Spinocerebellar Ataxia Study, But Zavegepant PDUFA Date Set
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.
You may also be interested in...
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
With Nurtec and zavegepant in hand from Bristol, Biohaven tries for another success with a spinal muscular atrophy asset. It will move into epilepsy indications with the buyout of Channel, a subsidiary of Knopp.
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.